- Home
- GLED vs ADCT Comparison
GLED vs ADCT Comparison
Compare GLED & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLED | ADCT |
|---|---|---|
| Founded | N/A | 2011 |
| Country | | Switzerland |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.0M | 136.1M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GLED | ADCT |
|---|---|---|
| Price | $10.02 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 12.5K | ★ 1.8M |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $9.93 | $0.78 |
| 52 Week High | $10.06 | $4.98 |
Technical Indicators
Market Signals| Indicator | GLED | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 58.22 | 45.07 |
| Support Level | $9.94 | $1.03 |
| Resistance Level | N/A | $1.20 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 44.44 | 36.69 |
Price Performance
Historical ComparisonAbout GLED GalaxyEdge Acquisition Corporation Ordinary Shares
GalaxyEdge Acquisition Corp is a newly organized blank check company. The company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).